Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
The 2nd International Workshop on GPRC5D-targeted myeloma therapies (iwGPRC5D) took place in New York City, NY, on 12-13 March, 2026. This workshop brought together leading clinical and translational researchers to discuss the latest advances in GPRC5D-targeted therapies for multiple myeloma. iwGPRC5D 2026 was supported by BMS and Johnson & Johnson. Enduring content from the workshop is supported by AstraZeneca. Supporters have no influence over the production of the content.
iwGPRC5D 2026
International Workshop on GPRC5D-targeted therapies
12–13 March 2026 | New York, NY
The 2nd International Workshop on GPRC5D-targeted myeloma therapies (iwGPRC5D) took place in New York City, NY, on 12-13 March, 2026. This workshop brought together leading clinical and translational researchers to discuss the latest advances in GPRC5D-targeted therapies for multiple myeloma. iwGPRC5D 2026 was supported by BMS and Johnson & Johnson. Enduring content from the workshop is supported by AstraZeneca. Supporters have no influence over the production of the content.
Testing & diagnostics P1: diagnostic approaches & new technologies
Immunohistochemistry
Ozgur Can Eren Memorial Sloan Kettering Cancer Center, New York City, NY, United States
NGS technologies to meet today’s requirements and challenges
Daniel Auclair Multiple Myeloma Research Foundation (MMRF), Norwalk, CT, United States
Microbiome assessments
Kevin Miller Memorial Sloan Kettering Cancer Center, New York City, NY, United States
The advantages and limitations of clinical sequencing tests in multiple myeloma
Jonathan Keats TGen, Phoenix, AZ, United States
Basic & translational
What have we learnt about resistance to GPRC5D therapies?
Nizar Bahlis University of Calgary, Calgary, Canada
How do emerging translational studies influence sequencing?
MuralI Janakiram City of Hope, Duarte, CA, United States
Clinical updates
GPRC5D directed CAR T-cells
Jesús Berdeja Tennessee Oncology & SCRI, Nashville, TN, United States
GPRC5D antibody-drug conjugates
Omar Nadeem Dana-Farber Cancer Institute, Boston, MA, United States
GPRC5D T-cell engagers
Andrew Yee Massachusetts General Hospital, Boston, MA, United States
GPRC5D trispecific T-cell engagers
Saad Usmani Memorial Sloan Kettering Cancer Center, New York, NY, United States
Multi-antigen targeting
Yael Cohen Sourasky Medical Center, Tel-Aviv, Israel
Practical aspects of GPRC5D therapies
Real-world outcomes with talquetamab
Carlyn Rose Tan Memorial Sloan Kettering Cancer Center, New York City, NY, United States
Infectious complications
Tomáš Jelínek University of Ostrava, Ostrava, Czech Republic
Neurologic toxicities with GPRC5D therapies
Doris Hansen Moffitt Cancer Center, Tampa, FL, United States
GPRC5D-related ataxia
MuralI Janakiram City of Hope, Duarte, CA, United States
GI, skin, and oral toxicities
Joshua Richter Mount Sinai Medical Center, NY, United States
Emerging use of GPRC5D therapies
Talquetamab as bridging for BCMA CAR T-cells
Binod Dhakal Medical College of Wisconsin, Milwaukee, WI, United States
GPRC5D therapies for AL amyloidosis
Rajshekhar Chakraborty Columbia University Irving Medical Center, New York City, NY, United States
Is there a role for GPRC5D therapies in NDMM or early relapse?
Manisha Bhutani Atrium Health Levine Cancer Institute, Charlotte, NC, United States
Outpatient administration and remote monitoring
Sridevi Rajeeve Memorial Sloan Kettering Cancer Center, New York City, NY, United States
Translational approaches in GPRC5D-targeted therapies
Predictors of response and resistance to talquetamab
Tarek Mouhieddine Mount Sinai Medical Center, New York City, NY, United States
Immune profiling in GPRC5D therapies
Ross Firestone Memorial Sloan Kettering Cancer Center, Montvlae, NJ, United States
Coming soon!
Regulatory considerations for trial design & endpoints
Regulatory landscape: surrogate endpoints
Charlotte Pawlyn The Institute of Cancer Research, London, United Kingdom
Single or dual antigen targeting?
Hamza Hashmi Memorial Sloan Kettering Cancer Center, New York City, NY, United States
